<DOC>
	<DOCNO>NCT00798720</DOCNO>
	<brief_summary>The purpose study evaluate efficacy vorinostat bortezomib third line treatment advance NSCLC , well assess toxicity ( include neuropathy ) tolerability regimen .</brief_summary>
	<brief_title>Vorinostat Bortezomib Third-line Treatment Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Current treatment non-small cell lung cancer ( NSCLC ) remain inadequate . Vorinostat novel agent inhibits enzymatic activity histone deacetylases ( HDACs ) . Bortezomib small molecule proteasome inhibitor . Preclinical clinical study show advantage combine two agent treatment NSCLC</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Pathologically/histologically confirm NSCLC Advance NSCLC ( stage IIIB w/ effusion , stage IV , recurrent disease ) Measurable disease Two prior systemic anticancer ( cytotoxic biologic ) regimens advanced/metastatic disease , include one ( 1 ) platinumbased chemotherapy Prior treatment allow side effect resolve 3 week pass since last dose treatment ( 1 week palliative radiation therapy ) ECOG performance status 0 , 1 , 2 Patients brain metastasis allow , clinically stable treatment Normal liver , kidney , marrow function 18 year age older Negative pregnancy test woman childbearing potential . Life expectancy 3 month No concurrent use antitumor agent Prior therapy vorinostat , HDAC inhibitor , bortezomib Preexisting neuropathy grade &gt; /= 2 Myocardial infarction within 6 month prior enrollment NY Heart Association Class III Class IV heart failure Have take valproic acid &lt; /= 4 week prior enrollment Previous current malignancy histology within past 5 year , except cervical carcinoma situ adequately treat basal cell squamous cell carcinoma skin Hypersensitivity bortezomib , boron , mannitol Serious medical psychiatric illness likely interfere participation clinical study Pregnant woman HIV positive patient Hepatitis infection ( HCV HBV ) patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>HDAC</keyword>
	<keyword>proteasome inhibitor</keyword>
</DOC>